Abstract
Incubation of neostigmine with normal human plasma in vitro results in the formation of two quaternary nitrogen compounds, one of which has been identified as m-hydroxyphenyltrimethylammonium. This hydrolysis is prevented by prior addition of dyflos to plasma in concentrations sufficient to inhibit plasma cholinesterase activity. The significance of these findings is discussed in relation to the occurrence of the same metabolic products in the urine of patients with myasthenia gravis treated with oral neostigmine. No equivalent findings are available for normal subjects since it was not considered justifiable to treat them with neostigmine.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- KALOW W., LINDSAY H. A. A comparison of optical and manometric methods for the assay of human serum cholinesterase. Can J Biochem Physiol. 1955 Jul;33(4):568–574. [PubMed] [Google Scholar]
- NOWELL P. T., SCOTT C. A., WILSON A. Determination of neostigmine and pyridostigmine in the urine of patients with myasthenia gravis. Br J Pharmacol Chemother. 1962 Jun;18:617–624. doi: 10.1111/j.1476-5381.1962.tb01181.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- WESCOE W. C., RIKER W. F., Jr, BEACH V. L. Studies on the inter-relationships of certain cholinergic compounds. III. The reactions between 3-acetoxy phenyltrimethylammonium methylsulfate, 3-hydroxy phenyltrimethylammonium bromide and cholinesterases. J Pharmacol Exp Ther. 1950 Jun;99(2):265–276. [PubMed] [Google Scholar]